

Date: August 04, 2023

To,

NSE LIMITED

EXCHANGE PLAZA, 5TH FLOOR,
PLOT NO. C/1, G BLOCK, BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.

SYMBOL: REMUS

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on August 04, 2023.

We wish to inform you that the Board of Directors of the Company in their meeting held today i.e. August 04, 2023 have approved in principle, a proposal to incorporate 2(Two) Subsidiaries and 2 (Two) Wholly Owned Subsidiaries outside India.

Disclosures as required under Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are enclosed herewith as Annexure – I to IV.

Kindly note that the meeting of the Board of Directors of the Company commenced at 04:00 p.m. and concluded at 05.15 P.M.

You are requested to take the aforesaid information on your record.

Thanking you

Yours Sincerely,

For, Remus Pharmaceuticals Limited

**PATEL DEVAL
BAKULKUMAR**

Digitally signed by PATEL DEVAL
BAKULKUMAR
Date: 2023.08.04 17:15:54
+05'30'

Deval Patel

Company Secretary

Membership No.: A60090

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE:

5900 Balcones Drive, STE 100 Austin, TX 78731

P: +1 6096 320 320

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536

Annexure - I

Details required under the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Relius Pharmaceuticals SRL or such other name as may be approved by the competent authority in Bolivia.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The Subsidiary once incorporated shall be a related party of the Company. Save and except what is mentioned above, the Promoter/ promoter group/ group companies are not interested in the transaction.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable other than the Government Approvals as may be required from competent authorities for incorporating company in Bolivia.
6.	Indicative time period for completion of the acquisition	Not Applicable
7.	Nature of consideration – whether cash consideration or share swap and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	The Company would subscribe to initial capital/shares. The Company would infuse up to USD 25,000 in Share Capital in one or more tranches.
9.	Percentage of shareholding/control acquired and/or number of shares acquired	99%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable since the company is yet to be incorporated.

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE: 5900 Balcones Drive, STE 100 Austin, TX 78731

P: +1 6096 320 320

E: remus@remuspharma.com | W: www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536

Annexure - II

Details required under the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Relius Pharmaceuticals LTDA. or such other name as may be approved by the competent authority in Guatemala
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The Subsidiary once incorporated shall be a related party of the Company. Save and except what is mentioned above, the Promoter/ promoter group/ group companies are not interested in the transaction.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable other than the Government Approvals as may be required from competent authorities for incorporating company in Guatemala.
6.	Indicative time period for completion of the acquisition	Not Applicable
7.	Nature of consideration – whether cash consideration or share swap and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	The Company would subscribe to initial capital/shares. The Company would infuse up to USD 25,000 in Share Capital in one or more tranches.
9.	Percentage of shareholding/control acquired and/or number of shares acquired	99%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable since the company is yet to be incorporated.

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE: 5900 Balcones Drive, STE 100 Austin, TX 78731
P: +1 6096 320 320

E: remus@remuspharma.com | W: www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536

Details required under the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Relius Pharmaceuticals CIA. LTDA. or such other name as may be approved by the competent authority in Ecuador.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The Wholly Owned Subsidiary once incorporated shall be a related party of the Company. Save and except what is mentioned above, the Promoter/ promoter group/ group companies are not interested in the transaction.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable other than the Government Approvals as may be required from competent authorities for incorporating company in Ecuador.
6.	Indicative time period for completion of the acquisition	Not Applicable
7.	Nature of consideration – whether cash consideration or share swap and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	The Company would subscribe to initial capital/shares. The Company would infuse up to USD 25,000 in Share Capital in one or more tranches.
9.	Percentage of shareholding/control acquired and/or number of shares acquired	100%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable since the company is yet to be incorporated.

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE: 5900 Balcones Drive, STE 100 Austin, TX 78731
P: +1 6096 320 320

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536

Details required under the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Relius Pharmaceuticals INC. or such other name as may be approved by the competent authority in USA
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The Wholly Owned Subsidiary once incorporated shall be a related party of the Company. Save and except what is mentioned above, the Promoter/ promoter group/ group companies are not interested in the transaction.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable other than the Government Approvals as may be required from competent authorities for incorporating company in USA.
6.	Indicative time period for completion of the acquisition	Not Applicable
7.	Nature of consideration – whether cash consideration or share swap and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	The Company would subscribe to initial capital/shares. The Company would infuse up to USD 25,000 in Share Capital in one or more tranches.
9.	Percentage of shareholding/control acquired and/or number of shares acquired	100%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable since the company is yet to be incorporated.

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE: 5900 Balcones Drive, STE 100 Austin, TX 78731

P: +1 6096 320 320

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536